ZA200809024B - 2-Pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial - Google Patents

2-Pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

Info

Publication number
ZA200809024B
ZA200809024B ZA200809024A ZA200809024A ZA200809024B ZA 200809024 B ZA200809024 B ZA 200809024B ZA 200809024 A ZA200809024 A ZA 200809024A ZA 200809024 A ZA200809024 A ZA 200809024A ZA 200809024 B ZA200809024 B ZA 200809024B
Authority
ZA
South Africa
Prior art keywords
inhibition
disease
beneficial
treatment
condition
Prior art date
Application number
ZA200809024A
Other languages
English (en)
Inventor
Peter Hansen
Karolina Lawitz
Matti Lepistoe
Hans Loenn
Asim Ray
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200809024(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200809024B publication Critical patent/ZA200809024B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA200809024A 2006-05-08 2008-10-21 2-Pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial ZA200809024B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79878606P 2006-05-08 2006-05-08

Publications (1)

Publication Number Publication Date
ZA200809024B true ZA200809024B (en) 2010-03-31

Family

ID=38667997

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809024A ZA200809024B (en) 2006-05-08 2008-10-21 2-Pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

Country Status (21)

Country Link
US (1) US7998984B2 (ja)
EP (1) EP2018375B1 (ja)
JP (1) JP2009536196A (ja)
KR (1) KR20090017573A (ja)
CN (1) CN101490033A (ja)
AR (1) AR060875A1 (ja)
AT (1) ATE459615T1 (ja)
AU (1) AU2007248950B2 (ja)
BR (1) BRPI0711357A2 (ja)
CA (1) CA2649813A1 (ja)
CL (1) CL2007001282A1 (ja)
DE (1) DE602007005120D1 (ja)
ES (1) ES2339607T3 (ja)
HK (1) HK1127599A1 (ja)
IL (1) IL194948A0 (ja)
MX (1) MX2008013836A (ja)
NO (1) NO20084872L (ja)
TW (1) TW200808763A (ja)
UY (1) UY30328A1 (ja)
WO (1) WO2007129962A1 (ja)
ZA (1) ZA200809024B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
PL2066662T3 (pl) * 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
DE102007031397A1 (de) * 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
US8466284B2 (en) * 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2508189A3 (de) * 2008-04-20 2012-11-07 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
ES2628219T3 (es) * 2009-05-19 2017-08-02 Vivia Biotech S.L. Métodos para proporcionar ensayos de medicina personalizada ex vivo para neoplasias hematológicas
CN102639505A (zh) * 2009-10-02 2012-08-15 阿斯利康(瑞典)有限公司 用作嗜中性白细胞弹性蛋白酶抑制剂的吡啶-2-酮化合物
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
JP2013177318A (ja) * 2010-06-30 2013-09-09 Dainippon Sumitomo Pharma Co Ltd ジヒドロピリミジノン誘導体およびその医薬用途
AU2012291041A1 (en) 2011-08-01 2014-03-13 Sumitomo Dainippon Pharma Co., Ltd. Uracil derivative and use thereof for medical purposes
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9409870B2 (en) 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds
MA43940A (fr) 2015-09-02 2018-12-12 Glaxosmithkline Ip No 2 Ltd Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
CN106674098B (zh) * 2016-12-23 2019-07-02 中国医科大学 N-(3-氰基-4-烷氧基苯基)吡啶甲酰胺类化合物及其用途
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
US20230218596A1 (en) 2020-04-16 2023-07-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) * 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
WO1998024780A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
PT1300396E (pt) 2000-06-12 2009-04-20 Eisai R&D Man Co Ltd Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
PT1357111E (pt) 2000-12-28 2009-10-20 Shionogi & Co Derivados de 2-piridona com afinidade para receptores de canabinóides do tipo 2
MXPA04001361A (es) * 2001-08-14 2004-05-27 Toyama Chemical Co Ltd Metodo novedoso para inhibir el crecimiento de virus y/o metodo virucida, y un analogo novedoso de un nucleotido de pirazina o de un nucleosido de pirazina.
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
DE60329981D1 (de) 2002-02-19 2009-12-24 Shionogi & Co Antipruriginosa
ES2293077T3 (es) 2002-08-27 2008-03-16 Bayer Healthcare Ag Derivados de dihidropiridinona como inhbidores de hne.
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
ATE516285T1 (de) 2004-02-19 2011-07-15 Bayer Schering Pharma Ag Dihydropyridinonderivate
ES2394177T3 (es) 2004-02-26 2013-01-23 Bayer Intellectual Property Gmbh 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR200365249Y1 (ko) * 2004-07-28 2004-10-21 추윤정 전동 퍼프
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
WO2007129060A1 (en) 2006-05-04 2007-11-15 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
US8466284B2 (en) 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Also Published As

Publication number Publication date
UY30328A1 (es) 2008-01-02
KR20090017573A (ko) 2009-02-18
TW200808763A (en) 2008-02-16
NO20084872L (no) 2009-02-03
US20090131486A1 (en) 2009-05-21
HK1127599A1 (en) 2009-10-02
DE602007005120D1 (de) 2010-04-15
AR060875A1 (es) 2008-07-16
MX2008013836A (es) 2008-11-10
ES2339607T3 (es) 2010-05-21
CN101490033A (zh) 2009-07-22
AU2007248950A1 (en) 2007-11-15
IL194948A0 (en) 2009-08-03
ATE459615T1 (de) 2010-03-15
EP2018375A1 (en) 2009-01-28
US7998984B2 (en) 2011-08-16
JP2009536196A (ja) 2009-10-08
CA2649813A1 (en) 2007-11-15
AU2007248950B2 (en) 2010-11-18
CL2007001282A1 (es) 2008-01-18
EP2018375B1 (en) 2010-03-03
WO2007129962A1 (en) 2007-11-15
BRPI0711357A2 (pt) 2011-09-27

Similar Documents

Publication Publication Date Title
HK1127599A1 (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
IL194949A0 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
ZA200710605B (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
PL2049127T3 (pl) N-metanokarbapochodne do leczenia chorób serca
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
LT2100508T (lt) Augalų ligų kontrolės kompozicija ir būdas skirtas augalų ligų prevencijai ir kontrolei
EP1984017A4 (en) PROCEDURE FOR THE THERAPY OR PROPHYLAXIS OF TISSUE DAMAGE CAUSED BY INCREASED BLEACHING
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
EP2069391A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING EYE DRYING
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
PL2234631T3 (pl) Związki i metody stosowane w terapii choroby naczyniowej
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
EP1843781A4 (en) COMPOSITION FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF INFLAMMATORY CHRONIC DISEASES OF AIRWAYS
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0623740D0 (en) Treatment of disease
ZA200708279B (en) Dermatological compositions and salts for the treatment of dermatological diseases
IL193319A0 (en) Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases